COLCRYS (colchicine, USP) tablets are indicated for prophylaxis and the treatment of acute gout flares. Prophylaxis of Gout Flares: COLCRYS is indicated for prophylaxis of gout flares. Treatment of Gout Flares: COLCRYS tablets are indicated for treatment of acute gout flares when taken at the first sign of a flare. COLCRYS (colchicine, USP) tablets are indicated in adults and children four years or older for treat...
The long-term use of colchicine is established for FMF and the prophylaxis of gout flares, but the safety and efficacy of repeat treatment for gout flares has not been evaluated. The dosing regimens for COLCRYS are different for each indication and must be individualized. The recommended dosage of COLCRYS depends on the patient's age, renal function, hepatic function and use of coadministered drugs [see Dosage and...
COLCRYS (colchicine, USP) tablets 0.6 mg are purple, film-coated, capsule-shaped tablets debossed with "AR 374" on one side and scored on the other side. Bottles of 30 NDC 64764-119-07 Bottles of 60 NDC 64764-119-06 Bottles of 100 NDC 64764-119-01 Bottles of 1000 NDC 64764-119-10 Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Protect from light. DISPENSE IN TIGHT, LIGHT-RESISTANT CONTA...
www.fda.gov/medwatch
www.COLCRYS.comCOLCRYS (colchicine, USP) tablets are indicated for prophylaxis and the treatment of acute gout flares.
COLCRYS (colchicine, USP) tablets are indicated in adults and children four years or older for treatment of familial Mediterranean fever (FMF).
The long-term use of colchicine is established for FMF and the prophylaxis of gout flares, but the safety and efficacy of repeat treatment for gout flares has not been evaluated. The dosing regimens for COLCRYS are different for each indication and must be individualized.
The recommended dosage of COLCRYS depends on the patient's age, renal function, hepatic function and use of coadministered drugs [see Dosage and Administration (2.4, 2.5, 2.6)].
COLCRYS tablets are administered orally without regard to meals.
COLCRYS is not an analgesic medication and should not be used to treat pain from other causes.
Prophylaxis of Gout Flares
The recommended dosage of COLCRYS for prophylaxis of gout flares for adults and adolescents older than 16 years of age is 0.6 mg once or twice daily. The maximum recommended dose for prophylaxis of gout flares is 1.2 mg/day.
An increase in gout flares may occur after initiation of uric acid-lowering therapy, including pegloticase, febuxostat and allopurinol, due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits. COLCRYS is recommended upon initiation of gout flare prophylaxis with uric acid-lowering therapy. Prophylactic therapy may be beneficial for at least the first six months of uric acid-lowering therapy.
Treatment of Gout Flares
The recommended dose of COLCRYS for treatment of a gout flare is 1.2 mg (two tablets) at the first sign of the flare followed by 0.6 mg (one tablet) one hour later. Higher doses have not been found to be more effective. The maximum recommended dose for treatment of gout flares is 1.8 mg over a 1-hour period. COLCRYS may be administered for treatment of a gout flare during prophylaxis at doses not to exceed 1.2 mg (two tablets) at the first sign of the flare followed by 0.6 mg (one tablet) one hour later. Wait 12 hours and then resume the prophylactic dose.
The recommended dosage of COLCRYS for FMF in adults is 1.2 mg to 2.4 mg daily.
COLCRYS should be increased as needed to control disease and as tolerated in increments of 0.3 mg/day to a maximum recommended daily dose. If intolerable side effects develop, the dose should be decreased in increments of 0.3 mg/day. The total daily COLCRYS dose may be administered in one to two divided doses.
Prophylaxis and Treatment of Gout Flares
COLCRYS is not recommended for pediatric use in prophylaxis or treatment of gout flares.
FMF
The recommended dosage of COLCRYS for FMF in pediatric patients 4 years of age and older is based on age. The following daily doses may be given as a single or divided dose twice daily:
Concomitant Therapy
Coadministration of COLCRYS with drugs known to inhibit CYP3A4 and/or P-glycoprotein (P-gp) increases the risk of colchicine-induced toxic effects (Table 1). If patients are taking or have recently completed treatment with drugs listed in Table 1 within the prior 14 days, the dose adjustments are as shown in the table below [see Drug Interactions (7)].
| Table 1. COLCRYS Dose Adjustment for Coadministration with Interacting Drugs if No Alternative Available* | |||||||
|---|---|---|---|---|---|---|---|
| Strong CYP3A4 Inhibitors† | |||||||
| Drug | Noted or Anticipated Outcome | Gout Flares | FMF | ||||
| Prophylaxis of Gout Flares | Treatment of Gout Flares | ||||||
| Original Intended Dosage | Adjusted Dose | Original Intended Dosage | Adjusted Dose | Original Intended Dosage | Adjusted Dose | ||
| Atazanavir Clarithromycin Darunavir/Ritonavir‡ Indinavir Itraconazole Ketoconazole Lopinavir/Ritonavir‡ Nefazodone Nelfinavir Ritonavir Saquinavir Telithromycin Tipranavir/Ritonavir‡ | Significant increase in colchicine plasma levels*; fatal colchicine toxicity has been reported with clarithromycin, a strong CYP3A4 inhibitor. Similarly, significant increase in colchicine plasma levels is anticipated with other strong CYP3A4 inhibitors. | 0.6 mg twice a day | 0.3 mg once a day | 1.2 mg (2 tablets) followed by 0.6 mg (1 tablet) 1 hour later. Dose to be repeated no earlier than 3 days. | 0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days. | Maximum daily dose of 1.2 – 2.4 mg | Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day) |
| 0.6 mg once a day | 0.3 mg once every other day | ||||||
| Moderate CYP3A4 Inhibitors | |||||||
| Drug | Noted or Anticipated Outcome | Gout Flares | FMF | ||||
| Prophylaxis of Gout Flares | Treatment of Gout Flares | ||||||
| Original Intended Dosage | Adjusted Dose | Original Intended Dosage | Adjusted Dose | Original Intended Dosage | Adjusted Dose | ||
| Amprenavir‡
Aprepitant Diltiazem Erythromycin Fluconazole Fosamprenavir‡ (prodrug of Amprenavir) Grapefruit juice Verapamil | Significant increase in colchicine plasma concentration is anticipated. Neuromuscular toxicity has been reported with diltiazem and verapamil interactions. | 0.6 mg twice a day | 0.3 mg twice a day or 0.6 mg once a day | 1.2 mg (2 tablets) followed by 0.6 mg (1 tablet) 1 hour later. Dose to be repeated no earlier than 3 days. | 1.2 mg (2 tablets) × 1 dose. Dose to be repeated no earlier than 3 days. | Maximum daily dose of 1.2 – 2.4 mg | Maximum daily dose of 1.2 mg (may be given as 0.6 mg twice a day) |
| 0.6 mg once a day | 0.3 mg once a day | ||||||
| P-gp Inhibitors† | |||||||
| Drug | Noted or Anticipated Outcome | Gout Flares | FMF | ||||
| Prophylaxis of Gout Flares | Treatment of Gout Flares | ||||||
| Original Intended Dosage | Adjusted Dose | Original Intended Dosage | Adjusted Dose | Original Intended Dosage | Adjusted Dose | ||
| Cyclosporine Ranolazine | Significant increase in colchicine plasma levels*; fatal colchicine toxicity has been reported with cyclosporine, a P-gp inhibitor. Similarly, significant increase in colchicine plasma levels is anticipated with other P-gp inhibitors. | 0.6 mg twice a day | 0.3 mg once a day | 1.2 mg (2 tablets) followed by 0.6 mg (1 tablet) 1 hour later. Dose to be repeated no earlier than 3 days. | 0.6 mg (1 tablet) × 1 dose. Dose to be repeated no earlier than 3 days. | Maximum daily dose of 1.2 – 2.4 mg | Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day) |
| 0.6 mg once a day | 0.3 mg once every other day | ||||||
* For magnitude of effect on colchicine plasma concentrations [see Clinical Pharmacology (12.3)]
† Patients with renal or hepatic impairment should not be given COLCRYS in conjunction with strong CYP3A4 or P-gp inhibitors [see Contraindications (4)]
‡ When used in combination with Ritonavir, see dosing recommendations for strong CYP3A4 inhibitors [see Contraindications (4)]
| Table 2. COLCRYS Dose Adjustment for Coadministration with Protease Inhibitors | |||||
|---|---|---|---|---|---|
| Protease Inhibitor | Clinical Comment | w/Colchicine - Prophylaxis of Gout Flares | w/Colchicine - Treatment of Gout Flares | w/Colchicine - Treatment of FMF | |
| Atazanavir sulfate (Reyataz) | Patients with renal or hepatic impairment should not be given colchicine with Reyataz. | Original dose | Adjusted dose | 0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days. | Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day) |
| 0.6 mg twice a day | 0.3 mg once a day | ||||
| 0.6 mg once a day | 0.3 mg once every other day | ||||
| Darunavir (Prezista) | Patients with renal or hepatic impairment should not be given colchicine with Prezista/ritonavir. | Original dose | Adjusted dose | 0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days. | Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day) |
| 0.6 mg twice a day | 0.3 mg once a day | ||||
| 0.6 mg once a day | 0.3 mg once every other day | ||||
| Fosamprenavir (Lexiva) with Ritonavir | Patients with renal or hepatic impairment should not be given colchicine with Lexiva/ritonavir. | Original dose | Adjusted dose | 0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days. | Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day) |
| 0.6 mg twice a day | 0.3 mg once a day | ||||
| 0.6 mg once a day | 0.3 mg once every other day | ||||
| Fosamprenavir (Lexiva) | Patients with renal or hepatic impairment should not be given colchicine with Lexiva/ritonavir. | Original dose | Adjusted dose | 1.2 mg (2 tablets) × 1 dose. Dose to be repeated no earlier than 3 days. | Maximum daily dose of 1.2 mg (may be given as 0.6 mg twice a day) |
| 0.6 mg twice a day | 0.3 mg twice a day or 0.6 mg once a day | ||||
| 0.6 mg once a day | 0.3 mg once a day | ||||
| Indinavir (Crixivan) | Patients with renal or hepatic impairment should not be given colchicine with Crixivan. | Original dose | Adjusted dose | 0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days. | Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day) |
| 0.6 mg twice a day | 0.3 mg once a day | ||||
| 0.6 mg once a day | 0.3 mg once every other day | ||||
| Lopinavir/Ritonavir (Kaletra) | Patients with renal or hepatic impairment should not be given colchicine with Kaletra. | Original dose | Adjusted dose | 0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days. | Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day) |
| 0.6 mg twice a day | 0.3 mg once a day | ||||
| 0.6 mg once a day | 0.3 mg once every other day | ||||
| Nelfinavir mesylate (Viracept) | Patients with renal or hepatic impairment should not be given colchicine with Viracept. | Original dose | Adjusted dose | 0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days. | Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day) |
| 0.6 mg twice a day | 0.3 mg once a day | ||||
| 0.6 mg once a day | 0.3 mg once every other day | ||||
| Ritonavir (Norvir) | Patients with renal or hepatic impairment should not be given colchicine with Norvir. | Original dose | Adjusted dose | 0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days. | Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day) |
| 0.6 mg twice a day | 0.3 mg once a day | ||||
| 0.6 mg once a day | 0.3 mg once every other day | ||||
| Saquinavir mesylate (Invirase) | Patients with renal or hepatic impairment should not be given colchicine with Invirase/ ritonavir. | Original dose | Adjusted dose | 0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days. | Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day) |
| 0.6 mg twice a day | 0.3 mg once a day | ||||
| 0.6 mg once a day | 0.3 mg once every other day | ||||
| Tipranavir (Aptivus) | Patients with renal or hepatic impairment should not be given colchicine with Aptivus/ritonavir. | Original dose | Adjusted dose | 0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days. | Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day) |
| 0.6 mg twice a day | 0.3 mg once a day | ||||
| 0.6 mg once a day | 0.3 mg once every other day | ||||
Treatment of gout flares with COLCRYS is not recommended in patients receiving prophylactic dose of COLCRYS and CYP3A4 inhibitors.
Colchicine dosing must be individualized according to the patient's renal function [see Use in Specific Populations (8.6)].
Clcr in mL/minute may be estimated from serum creatinine (mg/dL) determination using the following formula:
| [140-age (years) × weight (kg)] | |
| Clcr = | 72 × serum creatinine (mg/dL) × 0.85 for female patients |
Gout Flares
Prophylaxis of Gout Flares
For prophylaxis of gout flares in patients with mild (estimated creatinine clearance [Clcr] 50 to 80 mL/min) to moderate (Clcr 30 to 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, in patients with severe impairment, the starting dose should be 0.3 mg/day and any increase in dose should be done with close monitoring. For the prophylaxis of gout flares in patients undergoing dialysis, the starting doses should be 0.3 mg given twice a week with close monitoring [see Clinical Pharmacology (12.3), Use in Specific Populations (8.6)].
Treatment of Gout Flares
For treatment of gout flares in patients with mild (Clcr 50 to 80 mL/min) to moderate (Clcr 30 to 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, in patients with severe impairment, while the dose does not need to be adjusted for the treatment of gout flares, a treatment course should be repeated no more than once every two weeks. For patients with gout flares requiring repeated courses, consideration should be given to alternate therapy. For patients undergoing dialysis, the total recommended dose for the treatment of gout flares should be reduced to a single dose of 0.6 mg (one tablet). For these patients, the treatment course should not be repeated more than once every two weeks [see Clinical Pharmacology (12.3), Use in Specific Populations (8.6)].
Treatment of gout flares with COLCRYS is not recommended in patients with renal impairment who are receiving COLCRYS for prophylaxis.
FMF
Caution should be taken in dosing patients with moderate and severe renal impairment and in patients undergoing dialysis. For these patients, the dosage should be reduced [see Clinical Pharmacology (12.3)]. Patients with mild (Clcr 50 to 80 mL/min) and moderate (Clcr 30 to 50 mL/min) renal impairment should be monitored closely for adverse effects of COLCRYS. Dose reduction may be necessary. For patients with severe renal failure (Clcr less than 30 mL/min), start with 0.3 mg/day; any increase in dose should be done with adequate monitoring of the patient for adverse effects of colchicine [see Use in Specific Populations (8.6)]. For patients undergoing dialysis, the total recommended starting dose should be 0.3 mg (half tablet) per day. Dosing can be increased with close monitoring. Any increase in dose should be done with adequate monitoring of the patient for adverse effects of colchicine [see Clinical Pharmacology (12.3), Use in Specific Populations (8.6)].
Gout Flares
Prophylaxis of Gout Flares
For prophylaxis of gout flares in patients with mild to moderate hepatic function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. Dose reduction should be considered for the prophylaxis of gout flares in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].
Treatment of Gout Flares
For treatment of gout flares in patients with mild to moderate hepatic function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, for the treatment of gout flares in patients with severe impairment, while the dose does not need to be adjusted, a treatment course should be repeated no more than once every two weeks. For these patients, requiring repeated courses for the treatment of gout flares, consideration should be given to alternate therapy [see Use in Specific Populations (8.7)].
Treatment of gout flares with COLCRYS is not recommended in patients with hepatic impairment who are receiving COLCRYS for prophylaxis.
FMF
Patients with mild to moderate hepatic impairment should be monitored closely for adverse effects of colchicine. Dose reduction should be considered in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].
Tablets: 0.6 mg colchicine — purple capsule-shaped, film-coated with "AR 374" debossed on one side and scored on the other side.
Patients with renal or hepatic impairment should not be given COLCRYS in conjunction with P-gp or strong CYP3A4 inhibitors (this includes all protease inhibitors except fosamprenavir). In these patients, life-threatening and fatal colchicine toxicity has been reported with colchicine taken in therapeutic doses.
Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine [see Overdosage (10)]. COLCRYS should be kept out of the reach of children.
Myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia and aplastic anemia have been reported with colchicine used in therapeutic doses.
Colchicine is a P-gp and CYP3A4 substrate. Life-threatening and fatal drug interactions have been reported in patients treated with colchicine given with P-gp and strong CYP3A4 inhibitors. If treatment with a P-gp or strong CYP3A4 inhibitor is required in patients with normal renal and hepatic function, the patient's dose of colchicine may need to be reduced or interrupted [see Drug Interactions (7)]. Use of COLCRYS in conjunction with P-gp or strong CYP3A4 inhibitors (this includes all protease inhibitors except fosamprenavir) is contraindicated in patients with renal or hepatic impairment [see Contraindications (4)].
Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses. Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk. Concomitant use of atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, gemfibrozil, fenofibrate, fenofibric acid or benzafibrate (themselves associated with myotoxicity) or cyclosporine with COLCRYS may potentiate the development of myopathy [see Drug Interactions (7)]. Once colchicine is stopped, the symptoms generally resolve within one week to several months.
Prophylaxis of Gout Flares
The most commonly reported adverse reaction in clinical trials of colchicine for the prophylaxis of gout was diarrhea.
Treatment of Gout Flares
The most common adverse reactions reported in the clinical trial with COLCRYS for treatment of gout flares were diarrhea (23%) and pharyngolaryngeal pain (3%).
FMF
Gastrointestinal tract adverse effects are the most frequent side effects in patients initiating COLCRYS, usually presenting within 24 hours, and occurring in up to 20% of patients given therapeutic doses. Typical symptoms include cramping, nausea, diarrhea, abdominal pain and vomiting. These events should be viewed as dose-limiting if severe, as they can herald the onset of more significant toxicity.
Because clinical studies are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice.
In a randomized, double-blind, placebo-controlled trial in patients with a gout flare, gastrointestinal adverse reactions occurred in 26% of patients using the recommended dose (1.8 mg over one hour) of COLCRYS compared to 77% of patients taking a nonrecommended high dose (4.8 mg over six hours) of colchicine and 20% of patients taking placebo. Diarrhea was the most commonly reported drug-related gastrointestinal adverse event. As shown in Table 3, diarrhea is associated with COLCRYS treatment. Diarrhea was more likely to occur in patients taking the high-dose regimen than the low-dose regimen. Severe diarrhea occurred in 19% and vomiting occurred in 17% of patients taking the nonrecommended high-dose colchicine regimen but did not occur in the recommended low-dose COLCRYS regimen.
| Table 3. Number (%) of Patients with at Least One Drug-Related Treatment-Emergent Adverse Event with an Incidence of ≥2% of Patients in Any Treatment Group | |||
|---|---|---|---|
| MedDRA System Organ Class MedDRA Preferred Term | COLCRYS Dose | Placebo (N=59) n (%) | |
| High (N=52) n (%) | Low (N=74) n (%) | ||
| Number of Patients with at Least One Drug-Related TEAE | 40 (77) | 27 (37) | 16 (27) |
| Gastrointestinal Disorders | 40 (77) | 19 (26) | 12 (20) |
| Diarrhea | 40 (77) | 17 (23) | 8 (14) |
| Nausea | 9 (17) | 3 (4) | 3 (5) |
| Vomiting | 9 (17) | 0 | 0 |
| Abdominal Discomfort | 0 | 0 | 2 (3) |
| General Disorders and Administration Site Conditions | 4 (8) | 1 (1) | 1 (2) |
| Fatigue | 2 (4) | 1 (1) | 1 (2) |
| Metabolic and Nutrition Disorders | 0 | 3 (4) | 2 (3) |
| Gout | 0 | 3 (4) | 1 (2) |
| Nervous System Disorders | 1 (2) | 1 (1.4) | 2 (3) |
| Headache | 1 (2) | 1 (1) | 2 (3) |
| Respiratory Thoracic Mediastinal Disorders | 1 (2) | 2 (3) | 0 |
| Pharyngolaryngeal Pain | 1 (2) | 2 (3) | 0 |
Serious toxic manifestations associated with colchicine include myelosuppression, disseminated intravascular coagulation and injury to cells in the renal, hepatic, circulatory and central nervous systems.
These most often occur with excessive accumulation or overdosage [see Overdosage (10)].
The following adverse reactions have been identified with colchicine. These have been generally reversible upon temporarily interrupting treatment or lowering the dose of colchicine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Neurological: sensory motor neuropathy
Dermatological: alopecia, maculopapular rash, purpura, rash
Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting
Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia
Hepatobiliary: elevated AST, elevated ALT
Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis
Reproductive: azoospermia, oligospermia
COLCRYS (colchicine) is a substrate of the efflux transporter P-glycoprotein (P-gp). Of the cytochrome P450 enzymes tested, CYP3A4 was mainly involved in the metabolism of colchicine. If COLCRYS is administered with drugs that inhibit P-gp, most of which also inhibit CYP3A4, increased concentrations of colchicine are likely. Fatal drug interactions have been reported.
Physicians should ensure that patients are suitable candidates for treatment with COLCRYS and remain alert for signs and symptoms of toxicities related to increased colchicine exposure as a result of a drug interaction. Signs and symptoms of COLCRYS toxicity should be evaluated promptly and, if toxicity is suspected, COLCRYS should be discontinued immediately.
Table 4 provides recommendations as a result of other potentially significant drug interactions. Table 1 provides recommendations for strong and moderate CYP3A4 inhibitors and P-gp inhibitors.
| Table 4. Other Potentially Significant Drug Interactions | ||
|---|---|---|
| Concomitant Drug Class or Food | Noted or Anticipated Outcome | Clinical Comment |
| HMG-Co A Reductase Inhibitors: atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin | Pharmacokinetic and/or pharmacodynamic interaction: the addition of one drug to a stable long-term regimen of the other has resulted in myopathy and rhabdomyolysis (including a fatality) | Weigh the potential benefits and risks and carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during initial therapy; monitoring CPK (creatine phosphokinase) will not necessarily prevent the occurrence of severe myopathy. |
| Other Lipid-Lowering Drugs: fibrates, gemfibrozil | ||
| Digitalis Glycosides: digoxin | P-gp substrate; rhabdomyolysis has been reported | |
Risk Summary
Available data from published literature on colchicine use in pregnancy over several decades have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). Colchicine crosses the human placenta. Although animal reproductive and developmental studies were not conducted with COLCRYS (colchicine), published animal reproduction and development studies indicate that colchicine causes embryofetal toxicity, teratogenicity and altered postnatal development at exposures within or above the clinical therapeutic range.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data
Human Data
Available data from published observational studies, case series, and case reports over several decades do not suggest an increased risk for major birth defects or miscarriage in pregnant women with rheumatic diseases (such as rheumatoid arthritis, Behcet's disease, or familial Mediterranean fever (FMF) treated with colchicine at therapeutic doses during pregnancy. Limitations of these data include the lack of randomization and inability to control for confounders such as underlying maternal disease and maternal use of concomitant medications.
Risk Summary
Colchicine is present in human milk (see Data). Adverse events in breastfed infants have not been reported in the published literature after administration of colchicine to lactating women. There are no data on the effects of colchicine on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for COLCRYS and any potential adverse effects on the breastfed child from COLCRYS or from the underlying maternal condition.
Data
Limited published data from case reports and a small lactation study demonstrate that colchicine is present in breastmilk. A systematic review of literature reported no adverse effects in 149 breastfed children. In a prospective observational cohort study, no gastrointestinal or other symptoms were reported in 38 colchicine-exposed breastfed infants.
Infertility
Case reports and epidemiology studies in human male subjects on colchicine therapy indicated that infertility from colchicine is rare and may be reversible. A case report indicated that azoospermia was reversed when therapy was stopped. Case reports and epidemiology studies in female subjects on colchicine therapy have not established a clear relationship between colchicine use and female infertility. However, since the progression of FMF without treatment may result in infertility, the use of colchicine needs to be weighed against the potential risks [see Nonclinical Toxicology (13.1)].
The safety and efficacy of colchicine in children of all ages with FMF has been evaluated in uncontrolled studies. There does not appear to be an adverse effect on growth in children with FMF treated long-term with colchicine.
Safety and effectiveness of colchicine in pediatric patients with gout has not been established.
Clinical studies with colchicine for prophylaxis and treatment of gout flares and for treatment of FMF did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient with gout should be cautious, reflecting the greater frequency of decreased renal function, concomitant disease or other drug therapy [see Dosage and Administration (2.4), Clinical Pharmacology (12.3)].
Colchicine is significantly excreted in urine in healthy subjects. Clearance of colchicine is decreased in patients with impaired renal function. Total body clearance of colchicine was reduced by 75% in patients with end-stage renal disease undergoing dialysis.
Prophylaxis of Gout Flares
For prophylaxis of gout flares in patients with mild (estimated creatinine clearance Clcr 50 to 80 mL/min) to moderate (Clcr 30 to 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, in patients with severe impairment, the starting dose should be 0.3 mg per day and any increase in dose should be done with close monitoring. For the prophylaxis of gout flares in patients undergoing dialysis, the starting doses should be 0.3 mg given twice a week with close monitoring [see Dosage and Administration (2.5)].
Treatment of Gout Flares
For treatment of gout flares in patients with mild (Clcr 50 to 80 mL/min) to moderate (Clcr 30 to 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of COLCRYS. However, in patients with severe impairment, while the dose does not need to be adjusted for the treatment of gout flares, a treatment course should be repeated no more than once every two weeks. For patients with gout flares requiring repeated courses, consideration should be given to alternate therapy. For patients undergoing dialysis, the total recommended dose for the treatment of gout flares should be reduced to a single dose of 0.6 mg (one tablet). For these patients, the treatment course should not be repeated more than once every two weeks [see Dosage and Administration (2.5)].
FMF
Although pharmacokinetics of colchicine in patients with mild (Clcr 50 to 80 mL/min) and moderate (Clcr 30 to 50 mL/min) renal impairment is not known, these patients should be monitored closely for adverse effects of colchicine. Dose reduction may be necessary. In patients with severe renal failure (Clcr less than 30 mL/min) and end-stage renal disease requiring dialysis, COLCRYS may be started at the dose of 0.3 mg/day. Any increase in dose should be done with adequate monitoring of the patient for adverse effects of COLCRYS [see Clinical Pharmacology (12.3), Dosage and Administration (2.5)].
The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subjects [see Clinical Pharmacology (12.3)].
Prophylaxis of Gout Flares
For prophylaxis of gout flares in patients with mild to moderate hepatic function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. Dose reduction should be considered for the prophylaxis of gout flares in patients with severe hepatic impairment [see Dosage and Administration (2.6)].
Treatment of Gout Flares
For treatment of gout flares in patients with mild to moderate hepatic function impairment, adjustment of the recommended COLCRYS dose is not required, but patients should be monitored closely for adverse effects of COLCRYS. However, for the treatment of gout flares in patients with severe impairment, while the dose does not need to be adjusted, the treatment course should be repeated no more than once every two weeks. For these patients, requiring repeated courses for the treatment of gout flares, consideration should be given to alternate therapy [see Dosage and Administration (2.6)].
FMF
In patients with severe hepatic disease, dose reduction should be considered with careful monitoring [see Clinical Pharmacology (12.3), Dosage and Administration (2.6)].
Tolerance, abuse or dependence with colchicine has not been reported.
The exact dose of colchicine that produces significant toxicity is unknown. Fatalities have occurred after ingestion of a dose as low as 7 mg over a four day period, while other patients have survived after ingesting more than 60 mg. A review of 150 patients who overdosed on colchicine found that those who ingested less than 0.5 mg/kg survived and tended to have milder toxicities such as gastrointestinal symptoms, whereas those who took 0.5 to 0.8 mg/kg had more severe reactions such as myelosuppression. There was 100% mortality in those who ingested more than 0.8 mg/kg.
The first stage of acute colchicine toxicity typically begins within 24 hours of ingestion and includes gastrointestinal symptoms such as abdominal pain, nausea, vomiting, diarrhea and significant fluid loss, leading to volume depletion. Peripheral leukocytosis may also be seen. Life-threatening complications occur during the second stage, which occurs 24 to 72 hours after drug administration, attributed to multiorgan failure and its consequences. Death is usually a result of respiratory depression and cardiovascular collapse. If the patient survives, recovery of multiorgan injury may be accompanied by rebound leukocytosis and alopecia starting about one week after the initial ingestion.
Treatment of colchicine poisoning should begin with gastric lavage and measures to prevent shock. Otherwise, treatment is symptomatic and supportive. No specific antidote is known. Colchicine is not effectively removed by dialysis [see Clinical Pharmacology (12.3)].
Colchicine is an alkaloid chemically described as (S)N- (5,6,7,9-tetrahydro- 1,2,3, 10-tetramethoxy-9-oxobenzo [alpha] heptalen-7-yl) acetamide with a molecular formula of C22H25NO6 and a molecular weight of 399.4. The structural formula of colchicine is given below.
Colchicine occurs as a pale yellow powder that is soluble in water.
COLCRYS (colchicine, USP) tablets are supplied for oral administration as purple, film-coated, capsule-shaped tablets (0.1575" × 0.3030"), debossed with "AR 374" on one side and scored on the other, containing 0.6 mg of the active ingredient colchicine USP. Inactive ingredients: carnauba wax, FD&C blue #2, FD&C red #40, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, pregelatinized starch, sodium starch glycolate, titanium dioxide and triacetin.
The mechanism by which COLCRYS exerts its beneficial effect in patients with FMF has not been fully elucidated; however, evidence suggests that colchicine may interfere with the intracellular assembly of the inflammasome complex present in neutrophils and monocytes that mediates activation of interleukin-1β. Additionally, colchicine disrupts cytoskeletal functions through inhibition of β-tubulin polymerization into microtubules and consequently prevents the activation, degranulation and migration of neutrophils thought to mediate some gout symptoms.
Absorption
In healthy adults, COLCRYS is absorbed when given orally, reaching a mean Cmax of 2.5 ng/mL (range 1.1 to 4.4 ng/mL) in one to two hours (range 0.5 to 3 hours) after a single dose administered under fasting conditions.
Following oral administration of COLCRYS given as 1.8 mg colchicine over one hour to healthy, young adults under fasting conditions, colchicine appears to be readily absorbed, reaching mean maximum plasma concentrations of 6.2 ng/mL at a median 1.81 hours (range: 1.0 to 2.5 hours). Following administration of the nonrecommended high-dose regimen (4.8 mg over six hours), mean maximal plasma concentrations were 6.8 ng/mL, at a median 4.47 hours (range: 3.1 to 7.5 hours).
After ten days on a regimen of 0.6 mg twice daily, peak concentrations are 3.1 to 3.6 ng/mL (range 1.6 to 6.0 ng/mL), occurring 1.3 to 1.4 hours postdose (range 0.5 to 3.0 hours). Mean pharmacokinetic parameter values in healthy adults are shown in Table 5.
| Table 5. Mean (%CV) Pharmacokinetic Parameters in Healthy Adults Given COLCRYS | ||||
|---|---|---|---|---|
| Cmax
(Colchicine ng/mL) | Tmax
*
(h) | Vd/F (L) | CL/F (L/hr) | t1/2
(h) |
| CL = Dose/AUC0-t (calculated from mean values) Vd = CL/Ke (calculated from mean values) | ||||
| COLCRYS 0.6 mg Single Dose (N=13) | ||||
| 2.5 (28.7) | 1.5 (1.0 – 3.0) | 341.5 (54.4) | 54.1 (31.0) | -- |
| COLCRYS 0.6 mg Twice Daily × 10 Days (N=13) | ||||
| 3.6 (23.7) | 1.3 (0.5 – 3.0) | 1150 (18.7) | 30.3 (19.0) | 26.6 (16.3) |
* Tmax mean (range)
In some subjects, secondary colchicine peaks are seen, occurring between three and 36 hours postdose and ranging from 39 to 155% of the height of the initial peak. These observations are attributed to intestinal secretion and reabsorption and/or biliary recirculation.
Absolute bioavailability is reported to be approximately 45%.
Administration of COLCRYS with food has no effect on the rate of colchicine absorption but does decrease the extent of colchicine by approximately 15%. This is without clinical significance.
Distribution
The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg.
Colchicine binding to serum protein is low, 39 ± 5%, primarily to albumin regardless of concentration.
Colchicine crosses the placenta (plasma levels in the fetus are reported to be approximately 15% of the maternal concentration). Colchicine also distributes into breast milk at concentrations similar to those found in the maternal serum [see Use in Specific Populations (8.1, 8.2)].
Metabolism
Colchicine is demethylated to two primary metabolites, 2-O-demethylcolchicine and 3-O-demethylcolchicine (2- and 3-DMC, respectively) and one minor metabolite, 10-O-demethylcolchicine (also known as colchiceine). In vitro studies using human liver microsomes have shown that CYP3A4 is involved in the metabolism of colchicine to 2- and 3-DMC. Plasma levels of these metabolites are minimal (less than 5% of parent drug).
Elimination/Excretion
In healthy volunteers (n=12), 40 to 65% of 1 mg orally administered colchicine was recovered unchanged in urine. Enterohepatic recirculation and biliary excretion are also postulated to play a role in colchicine elimination. Following multiple oral doses (0.6 mg twice daily), the mean elimination half-lives in young healthy volunteers (mean age 25 to 28 years of age) is 26.6 to 31.2 hours. Colchicine is a substrate of P-gp.
Extracorporeal Elimination
Colchicine is not removed by hemodialysis.
Special Populations
There is no difference between men and women in the pharmacokinetic disposition of colchicine.
Pediatric Patients
Pharmacokinetics of colchicine was not evaluated in pediatric patients.
Elderly
A published report described the pharmacokinetics of 1 mg oral colchicine tablet in four elderly women compared to six young healthy males. The mean age of the four elderly women was 83 years (range 75 to 93), mean weight was 47 kg (38 to 61 kg) and mean creatinine clearance was 46 mL/min (range 25 to 75 mL/min). Mean peak plasma levels and AUC of colchicine were two times higher in elderly subjects compared to young healthy males.
A pharmacokinetic study using a single oral dose of one 0.6 mg colchicine tablet was conducted in young healthy subjects (n=20) between the ages of 18 and 30 years and elderly subjects (n=18) between the ages of 60 and 70 years. Elderly subjects in this study had a median age of 62 years and a mean (±SD) age of 62.83 ± 2.83 years. A statistically significant difference in creatinine clearance (mean ± SD) was found between the two age groups (132.56 ± 23.16 mL/min for young vs 87.02 ± 17.92 mL/min for elderly subjects, respectively). The following pharmacokinetic parameter values (mean ± SD) were observed for colchicine in the young and elderly subjects, respectively: AUC0-inf (ng/hr/mL) 22.39 ± 6.95 and 25.01 ± 6.92; Cmax (ng/mL) 2.61 ± 0.71 and 2.56 ± 0.97; Tmax (hr) 1.38 ± 0.42 and 1.25 ± 0.43; apparent elimination half-life (hr) 24.92 ± 5.34 and 30.06 ± 10.78; and clearance (mL/min) 0.0321 ± 0.0091 and 0.0292 ± 0.0071.
Clinical studies with colchicine for prophylaxis and treatment of gout flares and for treatment of FMF did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently than younger patients. In general, dose selection for an elderly patient with gout should be cautious, reflecting the greater frequency of decreased renal function, concomitant disease or other drug therapy [see Dosage and Administration (2.4), Use in Specific Populations (8.5)].
Renal Impairment
Pharmacokinetics of colchicine in patients with mild and moderate renal impairment is not known. A published report described the disposition of colchicine (1 mg) in young adult men and women with FMF who had normal renal function or end-stage renal disease requiring dialysis. Patients with end-stage renal disease had 75% lower colchicine clearance (0.17 vs 0.73 L/hr/kg) and prolonged plasma elimination half-life (18.8 vs 4.4 hours) as compared to subjects with FMF and normal renal function [see Dosage and Administration (2.5), Use in Specific Populations (8.6)].
Hepatic Impairment
Published reports on the pharmacokinetics of IV colchicine in patients with severe chronic liver disease, as well as those with alcoholic or primary biliary cirrhosis and normal renal function suggest wide interpatient variability. In some subjects with mild to moderate cirrhosis, the clearance of colchicine is significantly reduced and plasma half-life prolonged compared to healthy subjects. In subjects with primary biliary cirrhosis, no consistent trends were noted [see Dosage and Administration (2.6), Use in Specific Populations (8.7)]. No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C).
Drug Interactions
In Vitro Drug Interactions
In vitro studies in human liver microsomes have shown that colchicine is not an inhibitor or inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 activity.
In Vivo Drug Interactions
The effects of coadministration of other drugs with COLCRYS on Cmax, AUC and Cmin are summarized in Table 6 (effect of other drugs on colchicine) and Table 7 (effect of colchicine on other drugs). For information regarding clinical recommendations, see Table 1 in Dose Modification for Coadministration of Interacting Drugs [see Dosage and Administration (2.4)].
| Table 6. Drug Interactions: Pharmacokinetic Parameters for COLCRYS (Colchicine, USP) Tablets in the Presence of the Coadministered Drug | |||||
|---|---|---|---|---|---|
| Coadministered Drug | Dose of Coadministered Drug (mg) | Dose of COLCRYS (mg) | N | % Change in Colchicine Concentrations from Baseline (Range: Min - Max) | |
| Cmax | AUC0-t | ||||
| Cyclosporine | 100 mg single dose | 0.6 mg single dose | 23 | 270.0 (62.0 to 606.9) | 259.0 (75.8 to 511.9) |
| Clarithromycin | 250 mg twice daily, 7 days | 0.6 mg single dose | 23 | 227.2 (65.7 to 591.1) | 281.5 (88.7 to 851.6) |
| Ketoconazole | 200 mg twice daily, 5 days | 0.6 mg single dose | 24 | 101.7 (19.6 to 219.0) | 212.2 (76.7 to 419.6) |
| Ritonavir | 100 mg twice daily, 5 days | 0.6 mg single dose | 18 | 184.4 (79.2 to 447.4) | 296.0 (53.8 to 924.4) |
| Verapamil | 240 mg daily, 5 days | 0.6 mg single dose | 24 | 40.1 (-47.1 to 149.5) | 103.3 (-9.8 to 217.2) |
| Diltiazem | 240 mg daily, 7 days | 0.6 mg single dose | 20 | 44.2 (-46.0 to 318.3) | 93.4 (-30.2 to 338.6) |
| Azithromycin | 500 mg × 1 day, then 250 mg × 4 days | 0.6 mg single dose | 21 | 21.6 (-41.7 to 222.0) | 57.1 (-24.3 to 241.1) |
| Grapefruit juice | 240 mL twice daily, 4 days | 0.6 mg single dose | 21 | -2.55 (-53.4 to 55.0) | -2.36 (-46.4 to 62.2) |
Estrogen-containing oral contraceptives: In healthy female volunteers given ethinyl estradiol and norethindrone (Ortho-Novum 1/35) coadministered with COLCRYS (0.6 mg twice daily × 14 days), hormone concentrations are not affected.
In healthy volunteers given theophylline coadministered with COLCRYS (0.6 mg twice daily × 14 days), theophylline concentrations were not affected.
| Table 7. Drug Interactions: Pharmacokinetic Parameters for Coadministration of Drug in the Presence of COLCRYS (Colchicine, USP) Tablets | |||||
|---|---|---|---|---|---|
| Coadministered Drug | Dose of Coadministered Drug (mg) | Dose of COLCRYS (mg) | N | % Change in Coadministered Drug Concentrations from Baseline (Range: Min - Max) | |
| Cmax | AUC0-t | ||||
| Theophylline | 300 mg (elixir) single dose | 0.6 mg twice daily × 14 days | 27 | 1.6 (-30.4 to 23.1) | 1.6 (-28.5 to 27.1) |
| Ethinyl Estradiol (Ortho-Novum 1/35) | 21 day cycle (active treatment) + 7 day placebo | 0.6 mg twice daily × 14 days | 27* | -6.7 (-40.3 to 44.7) | -3.0†
(-25.3 to 24.9) |
| Norethindrone (Ortho-Novum 1/35) | 0.94 (-37.3 to 59.4) | -1.6†
(-32.0 to 33.7) | |||
Carcinogenesis
Two year studies were conducted in mice and rats to assess the carcinogenic potential of colchicine. No evidence of colchicine-related tumorigenicity was observed in mice or rats at colchicine oral doses up to 3 and 2 mg/kg/day, respectively (approximately six and eight times, respectively, the maximum recommended human dose of 2.4 mg on a mg/m2 basis).
Mutagenesis
Colchicine was negative for mutagenicity in the bacterial reverse mutation assay. In a chromosomal aberration assay in cultured human white blood cells, colchicine treatment resulted in the formation of micronuclei. Since published studies demonstrated that colchicine induces aneuploidy from the process of mitotic nondisjunction without structural DNA changes, colchicine is not considered clastogenic, although micronuclei are formed.
Impairment of Fertility
No studies of colchicine effects on fertility were conducted with COLCRYS. However, published nonclinical studies demonstrated that colchicine-induced disruption of microtubule formation affects meiosis and mitosis. Reproductive studies also reported abnormal sperm morphology and reduced sperm counts in males, and interference with sperm penetration, second meiotic division and normal cleavage in females when exposed to colchicine. Colchicine administered to pregnant animals resulted in fetal death and teratogenicity. These effects were dose-dependent, with the timing of exposure critical for the effects on embryofetal development. The nonclinical doses evaluated were generally higher than an equivalent human therapeutic dose, but safety margins for reproductive and developmental toxicity could not be determined.
The evidence for the efficacy of colchicine in patients with chronic gout is derived from the published literature. Two randomized clinical trials assessed the efficacy of colchicine 0.6 mg twice a day for the prophylaxis of gout flares in patients with gout initiating treatment with urate-lowering therapy. In both trials, treatment with colchicine decreased the frequency of gout flares.
The efficacy of a low-dosage regimen of oral colchicine (COLCRYS total dose 1.8 mg over one hour) for treatment of gout flares was assessed in a multicenter, randomized, double-blind, placebo-controlled, parallel group, one week, dose-comparison study. Patients meeting American College of Rheumatology criteria for gout were randomly assigned to three groups: high-dose colchicine (1.2 mg, then 0.6 mg hourly × 6 hours [4.8 mg total]); low-dose colchicine (1.2 mg, then 0.6 mg in one hour [1.8 mg total] followed by five placebo doses hourly); or placebo (two capsules, then one capsule hourly × six hours). Patients took the first dose within 12 hours of the onset of the flare and recorded pain intensity (11-point Likert scale) and adverse events over 72 hours. The efficacy of colchicine was measured based on response to treatment in the target joint, using patient self-assessment of pain at 24 hours following the time of first dose as recorded in the diary. A responder was one who achieved at least a 50% reduction in pain score at the 24-hour postdose assessment relative to the pretreatment score and did not use rescue medication prior to the actual time of 24-hour postdose assessment.
Rates of response were similar for the recommended low-dose treatment group (38%) and the nonrecommended high-dose group (33%) but were higher as compared to the placebo group (16%) as shown in Table 8.
| Table 8. Number (%) of Responders Based on Target Joint Pain Score at 24 Hours Post First Dose | ||||
|---|---|---|---|---|
| COLCRYS Dose Responders n (%) | % Differences in Proportion | |||
| Low-Dose (n=74) | High-Dose (n=52) | Placebo n (%) (n=58) | Low-Dose vs Placebo (95% CI) | High-Dose vs Placebo (95% CI) |
| 28 (38%) | 17 (33%) | 9 (16%) | 22 (8, 37) | 17 (1, 33) |
Figure 1 shows the percentage of patients achieving varying degrees of improvement in pain from baseline at 24 hours.
| Figure 1 Pain Relief on Low and High Doses of COLCRYS and Placebo (Cumulative) |
 |
The evidence for the efficacy of colchicine in patients with FMF is derived from the published literature. Three randomized, placebo-controlled studies were identified. The three placebo-controlled studies randomized a total of 48 adult patients diagnosed with FMF and reported similar efficacy endpoints as well as inclusion and exclusion criteria.
One of the studies randomized 15 patients with FMF to a six month crossover study during which five patients discontinued due to study noncompliance. The ten patients completing the study experienced five attacks over the course of 90 days while treated with colchicine compared to 59 attacks over the course of 90 days while treated with placebo. Similarly, the second study randomized 22 patients with FMF to a four month crossover study during which nine patients discontinued due to lack of efficacy while receiving placebo or study noncompliance. The 13 patients completing the study experienced 18 attacks over the course of 60 days while treated with colchicine compared to 68 attacks over the course of 60 days while treated with placebo. The third study was discontinued after an interim analysis of six of the 11 patients enrolled had completed the study; results could not be confirmed.
Open-label experience with colchicine in adults and children with FMF is consistent with the randomized, controlled trial experience and was utilized to support information on the safety profile of colchicine and for dosing recommendations.
COLCRYS (colchicine, USP) tablets 0.6 mg are purple, film-coated, capsule-shaped tablets debossed with "AR 374" on one side and scored on the other side.
| Bottles of 30 | NDC 64764-119-07 |
| Bottles of 60 | NDC 64764-119-06 |
| Bottles of 100 | NDC 64764-119-01 |
| Bottles of 1000 | NDC 64764-119-10 |
Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature].
Protect from light.
DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Dosing Instructions
Patients should be advised to take COLCRYS as prescribed, even if they are feeling better. Patients should not alter the dose or discontinue treatment without consulting with their doctor. If a dose of COLCRYS is missed:
Fatal Overdose
Instruct patient that fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine. COLCRYS should be kept out of the reach of children.
Blood Dyscrasias
Patients should be informed that bone marrow depression with agranulocytosis, aplastic anemia and thrombocytopenia may occur with COLCRYS.
Drug and Food Interactions
Patients should be advised that many drugs or other substances may interact with COLCRYS and some interactions could be fatal. Therefore, patients should report to their healthcare provider all of the current medications they are taking and check with their healthcare provider before starting any new medications, particularly antibiotics. Patients should also be advised to report the use of nonprescription medication or herbal products. Grapefruit and grapefruit juice may also interact and should not be consumed during COLCRYS treatment.
Neuromuscular Toxicity
Patients should be informed that muscle pain or weakness, tingling or numbness in fingers or toes may occur with COLCRYS alone or when it is used with certain other drugs. Patients developing any of these signs or symptoms must discontinue COLCRYS and seek medical evaluation immediately.
Infertility
Advise males of reproductive potential that COLCRYS may rarely and transiently impair fertility [see Use in Specific Populations (8.3)].
| This Medication Guide has been approved by the U.S. Food and Drug Administration COL243 R4 | Revised: May 2020 | ||
MEDICATION GUIDE | |||
Read the Medication Guide that comes with COLCRYS before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. You and your healthcare provider should talk about COLCRYS when you start taking it and at regular checkups. | |||
What is the most important information that I should know about COLCRYS? COLCRYS can cause serious side effects or death if levels of COLCRYS are too high in your body.
| |||
|
| ||
Ask your healthcare provider or pharmacist if you are not sure if you take any of the medicines listed above. This is not a complete list of all the medicines that can interact with COLCRYS.
| |||
What is COLCRYS? COLCRYS is a prescription medicine used to:
COLCRYS is not a pain medicine, and it should not be taken to treat pain related to other conditions unless specifically prescribed for those conditions. | |||
Who should not take COLCRYS? Do not take COLCRYS if you have liver or kidney problems and you take certain other medicines. Serious side effects, including death, have been reported in these patients even when taken as directed. See "What is the most important information that I should know about COLCRYS?". | |||
What should I tell my healthcare provider before starting COLCRYS? See "What is the most important information that I should know about COLCRYS?". Before you take COLCRYS, tell your healthcare provider about all your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including ones that you may only be taking for a short time, such as antibiotics. See "What is the most important information that I should know about COLCRYS?". Do not start a new medicine without talking to your healthcare provider. Using COLCRYS with certain other medicines, such as cholesterol-lowering medications and digoxin, can affect each other, causing serious side effects. Your healthcare provider may need to change your dose of COLCRYS. Talk to your healthcare provider about whether the medications you are taking might interact with COLCRYS and what side effects to look for. | |||
How should I take COLCRYS?
| |||
What should I avoid while taking COLCRYS? Avoid eating grapefruit or drinking grapefruit juice while taking COLCRYS. It can increase your chances of getting serious side effects. | |||
What are the possible side effects of COLCRYS? COLCRYS can cause serious side effects or even cause death. See "What is the most important information that I should know about COLCRYS?". Get medical help right away if you have:
Gout Flares: The most common side effect of COLCRYS in people who have gout flares is diarrhea. FMF: The most common side effects of COLCRYS in people who have FMF are abdominal pain, diarrhea, nausea and vomiting. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of COLCRYS. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | |||
How should I store COLCRYS?
Keep COLCRYS and all medicines out of the reach of children. | |||
General Information about COLCRYS Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use COLCRYS for a condition for which it was not prescribed. Do not give COLCRYS to other people, even if they have the same symptoms that you have. It may harm them. This Medication Guide summarizes the most important information about COLCRYS. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about COLCRYS that is written for healthcare professionals. | |||
What are the ingredients in COLCRYS? Active Ingredient: colchicine. Inactive Ingredients: carnauba wax, FD&C blue #2, FD&C red #40, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, pregelatinized starch, sodium starch glycolate, titanium dioxide and triacetin. Distributed by: COLCRYS is a trademark of Takeda Pharmaceuticals U.S.A., Inc., registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc. | |||
30 TABLETS
NDC 64764-119-07
COLCRYS®
(colchicine, USP) tablets
0.6 mg
PHARMACIST:
PLEASE DISPENSE WITH
MEDICATION GUIDE ATTACHED
Takeda
Rx only
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 64764-119-01 | EA - Each | 64764-119 | 52719dce-a115-4b80-bc47-74390c474842 | 1 | 2013-02-13 |
| 64764-119-07 | EA - Each | 64764-119 | 904dcc80-dd95-41f9-b226-965b46d41a86 | 1 | 2013-02-13 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Colchicine | ACTIVE INGREDIENT | SML2Y3J35T | 5 | |
| Colchicine | ACTIVE MOIETY | SML2Y3J35T | 5 | |
| carnauba wax | INACTIVE INGREDIENT | R12CBM0EIZ | 5 | |
| cellulose, microcrystalline | INACTIVE INGREDIENT | OP1R32D61U | 5 | |
| FD&C blue no. 2 | INACTIVE INGREDIENT | L06K8R7DQK | 5 | |
| FD&C red no. 40 | INACTIVE INGREDIENT | WZB9127XOA | 5 | |
| hypromelloses | INACTIVE INGREDIENT | 3NXW29V3WO | 5 | |
| lactose monohydrate | INACTIVE INGREDIENT | EWQ57Q8I5X | 5 | |
| magnesium stearate | INACTIVE INGREDIENT | 70097M6I30 | 5 | |
| polydextrose | INACTIVE INGREDIENT | VH2XOU12IE | 5 | |
| polyethylene glycols | INACTIVE INGREDIENT | 3WJQ0SDW1A | 5 | |
| sodium starch glycolate type A potato | INACTIVE INGREDIENT | 5856J3G2A2 | 5 | |
| starch, corn | INACTIVE INGREDIENT | O8232NY3SJ | 5 | |
| titanium dioxide | INACTIVE INGREDIENT | 15FIX9V2JP | 5 | |
| triacetin | INACTIVE INGREDIENT | XHX3C3X673 | 5 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 64764-119 | 64764-119-07, 64764-119-06, 64764-119-01, 64764-119-03, 64764-119-05, 64764-119-10 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 144 mg | ||
| triacetin | TRIACETIN | XHX3C3X673 | TABLET, COATED / ORAL | 1 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, COATED / ORAL | 49 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | GRANULE / ORAL | 629 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 24 mg | ||
| starch, corn | STARCH, CORN | O8232NY3SJ | TABLET / ORAL | 1116 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 9 mg | ||
| carnauba wax | CARNAUBA WAX | R12CBM0EIZ | TABLET, SUGAR COATED / ORAL | NA | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | LOTION / TOPICAL | 0.1 %w/w | ||
| FD&C red no. 40 | FD&C RED NO. 40 | WZB9127XOA | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | DROPS / ORAL | NA | ||
| FD&C red no. 40 | FD&C RED NO. 40 | WZB9127XOA | TABLET, EXTENDED RELEASE / ORAL | 2.22 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE / ORAL | 256.4 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | GRANULE, FOR SUSPENSION / ORAL | 1.7 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, COATED / ORAL | 1301 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION, EXTENDED RELEASE / ORAL | 71 mg | ||
| starch, corn | STARCH, CORN | O8232NY3SJ | TABLET, COATED / ORAL | 256 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, DELAYED RELEASE / ORAL | 144 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE / ORAL | 3990 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE / ORAL | 55 mg | ||
| FD&C blue no. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET, EXTENDED RELEASE / ORAL | 2.78 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, EXTENDED RELEASE / ORAL | 173 mg | ||
| FD&C red no. 40 | FD&C RED NO. 40 | WZB9127XOA | SHAMPOO / TOPICAL | 2 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CREAM / TOPICAL | 80 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / SUBLINGUAL | 505 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER / ORAL | 2 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE / ORAL | 2169 mg | ||
| FD&C blue no. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | CAPSULE / ORAL | 4 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg | ||
| FD&C red no. 40 | FD&C RED NO. 40 | WZB9127XOA | TABLET / SUBLINGUAL | NA | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, ORALLY DISINTEGRATING / ORAL | 41 mg | ||
| FD&C red no. 40 | FD&C RED NO. 40 | WZB9127XOA | CAPSULE, EXTENDED RELEASE / ORAL | 1 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / SUBLINGUAL | 43.2 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | INSERT / VAGINAL | 69 mg | ||
| FD&C red no. 40 | FD&C RED NO. 40 | WZB9127XOA | TABLET, FILM COATED / ORAL | 2.5 mg | ||
| FD&C red no. 40 | FD&C RED NO. 40 | WZB9127XOA | DROPS / ORAL | NA | ||
| triacetin | TRIACETIN | XHX3C3X673 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 2 mg | ||
| triacetin | TRIACETIN | XHX3C3X673 | TABLET / ORAL | 208 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | SUSPENSION/ DROPS / OPHTHALMIC | 3 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | INSERT / VAGINAL | 54.21 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, EXTENDED RELEASE / ORAL | 119.7 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 615 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INSERT / VAGINAL | 2282 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, SOLUBLE / BUCCAL | 11 mg | ||
| FD&C blue no. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET / BUCCAL | 0.01 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | PELLET / ORAL | 1140 mg | ||
| triacetin | TRIACETIN | XHX3C3X673 | TABLET, EXTENDED RELEASE / ORAL | 26 mg | ||
| FD&C red no. 40 | FD&C RED NO. 40 | WZB9127XOA | CONCENTRATE / ORAL | 0.04 mg/1ml | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION / INTRAMUSCULAR | 150 mg | ||
| carnauba wax | CARNAUBA WAX | R12CBM0EIZ | TABLET, DELAYED RELEASE / ORAL | 230 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | SUSPENSION / ORAL | 113 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, DELAYED RELEASE / ORAL | 1060 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | INHALANT / ORAL | 0.08 mg | ||
| carnauba wax | CARNAUBA WAX | R12CBM0EIZ | CAPSULE, EXTENDED RELEASE / ORAL | 288 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CREAM / VAGINAL | 586 mg | ||
| carnauba wax | CARNAUBA WAX | R12CBM0EIZ | GUM, CHEWING / BUCCAL | 10 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N022352-001 | COLCRYS | COLCHICINE | 0.6MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2009-07-29 |
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N022352-001 | 7964647 | 2028-10-06 | U-1007 | 2011-06-24 | |
| N022352-001 | 7964648 | 2028-10-06 | U-1161 | 2011-06-24 | |
| N022352-001 | 7981938 | 2028-10-06 | U-1166 | 2011-07-22 | |
| N022352-001 | 8093296 | 2028-10-06 | U-1007 | 2012-01-13 | |
| N022352-001 | 8093297 | 2028-10-06 | U-1161 | 2012-01-13 | |
| N022352-001 | 8093298 | 2028-10-06 | U-1116 | 2012-01-13 | |
| N022352-001 | 8097655 | 2028-10-06 | U-1020 | 2012-01-27 | |
| N022352-001 | 8415395 | 2028-10-06 | U-1007 | 2013-05-08 | |
| N022352-001 | 8415396 | 2028-10-06 | U-1007 | 2013-05-08 | |
| N022352-001 | 7619004 | 2028-12-03 | U-1020 | ||
| N022352-001 | 7935731 | 2028-12-03 | U-1116 | 2011-06-24 | |
| N022352-001 | 7601758 | 2029-02-10 | U-1007 | ||
| N022352-001 | 7820681 | 2029-02-17 | U-1020 | ||
| N022352-001 | 7906519 | 2029-02-17 | U-1116 | ||
| N022352-001 | 7915269 | 2029-02-17 | U-1007 | ||
| N022352-001 | 8440721 | 2029-02-17 | U-1007 | 2013-06-10 | |
| N022352-001 | 8440722 | 2029-02-17 | U-1020 | 2013-06-10 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | COLCRYS | 0.6MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2009-07-29 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | COLCRYS | 0.6MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2009-07-29 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N022352-001 | COLCRYS | 0.6MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2009-07-29 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N022352-001 | COLCRYS | 0.6MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2009-07-29 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | RLD | 2009-07-29 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | RLD | 2009-07-29 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | RLD | 2009-07-29 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | RLD | 2009-07-29 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | RLD | 2009-07-29 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | RLD | 2009-07-29 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | RLD | 2009-07-29 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | RLD | 2009-07-29 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | RLD | 2009-07-29 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | RLD | 2009-07-29 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | RLD | 2009-07-29 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | RLD | 2009-07-29 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N022352-001 | COLCRYS | 0.6MG | TABLET / ORAL | AB | RLD, RS | 2009-07-29 | 3a93d1ddd44b… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2024-05-31 18:47 UTC | 2024-05 | N022352-001 | AB | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N022352-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N022352-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N022352-001 | AB | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N022352-001 | AB | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N022352-001 | AB | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | N022352-001 | AB | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N022352-001 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N022352-001 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N022352-001 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N022352-001 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N022352-001 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N022352-001 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N022352-001 | AB | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N022352-001 | AB | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N022352-001 | AB | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | N022352-001 | AB | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N022352-001 | AB | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N022352-001 | AB | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N022352-001 | AB | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N022352-001 | AB | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | N022352-001 | AB | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | N022352-001 | AB | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N022352-001 | AB | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | N022352-001 | AB | 1 | f41ea6bd6efb… |
| 2022-09-29 23:25 UTC | 2022-09 | N022352-001 | AB | 1 | e64feba35796… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | N022352-001 | AB | 1 | cb3db0bc1861… |
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 7964647 | 2028-10-06 | U-1007 | 2011-06-24 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 7964648 | 2028-10-06 | U-1161 | 2011-06-24 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 7981938 | 2028-10-06 | U-1166 | 2011-07-22 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 8093296 | 2028-10-06 | U-1007 | 2012-01-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 8093297 | 2028-10-06 | U-1161 | 2012-01-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 8093298 | 2028-10-06 | U-1116 | 2012-01-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 8097655 | 2028-10-06 | U-1020 | 2012-01-27 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 8415395 | 2028-10-06 | U-1007 | 2013-05-08 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 8415396 | 2028-10-06 | U-1007 | 2013-05-08 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 7619004 | 2028-12-03 | U-1020 | c2088c7a36db… | ||
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 7935731 | 2028-12-03 | U-1116 | 2011-06-24 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 7601758 | 2029-02-10 | U-1007 | c2088c7a36db… | ||
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 7820681 | 2029-02-17 | U-1020 | c2088c7a36db… | ||
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 7906519 | 2029-02-17 | U-1116 | c2088c7a36db… | ||
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 7915269 | 2029-02-17 | U-1007 | c2088c7a36db… | ||
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 8440721 | 2029-02-17 | U-1007 | 2013-06-10 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022352-001 | 8440722 | 2029-02-17 | U-1020 | 2013-06-10 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 7964647 | 2028-10-06 | U-1007 | 2011-06-24 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 7964648 | 2028-10-06 | U-1161 | 2011-06-24 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 7981938 | 2028-10-06 | U-1166 | 2011-07-22 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 8093296 | 2028-10-06 | U-1007 | 2012-01-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 8093297 | 2028-10-06 | U-1161 | 2012-01-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 8093298 | 2028-10-06 | U-1116 | 2012-01-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 8097655 | 2028-10-06 | U-1020 | 2012-01-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 8415395 | 2028-10-06 | U-1007 | 2013-05-08 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 8415396 | 2028-10-06 | U-1007 | 2013-05-08 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 7619004 | 2028-12-03 | U-1020 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 7935731 | 2028-12-03 | U-1116 | 2011-06-24 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 7601758 | 2029-02-10 | U-1007 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 7820681 | 2029-02-17 | U-1020 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 7906519 | 2029-02-17 | U-1116 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 7915269 | 2029-02-17 | U-1007 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 8440721 | 2029-02-17 | U-1007 | 2013-06-10 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022352-001 | 8440722 | 2029-02-17 | U-1020 | 2013-06-10 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N022352-001 | 7964647 | 2028-10-06 | U-1007 | 2011-06-24 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N022352-001 | 7964648 | 2028-10-06 | U-1161 | 2011-06-24 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N022352-001 | 7981938 | 2028-10-06 | U-1166 | 2011-07-22 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N022352-001 | 8093296 | 2028-10-06 | U-1007 | 2012-01-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N022352-001 | 8093297 | 2028-10-06 | U-1161 | 2012-01-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N022352-001 | 8093298 | 2028-10-06 | U-1116 | 2012-01-13 | caaa826d4ba7… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 6f7b50e5-99b4-45e8-90d4-6aa8fc54a5a4 | 56c130d1-7581-4152-99a2-0014ee9366c0 | 2025-07-23 | Warnings, Adverse reactions | 6f7b50e5-99b4-45e8-90d4-6aa8fc54a5a4 56c130d1-7581-4152-99a2-0014ee9366c0 |
Adverse event summaries are temporarily unavailable. Other product information remains available.